Table 1 Clinical characteristics of study participants.
All (n = 123) | SU group (n = 63) | Non-SU group (n = 60) | p-value | |
|---|---|---|---|---|
Age, years | 59.9 ± 14.3 | 61.2 ± 12.8 | 58.5 ± 15.7 | 0.472 |
Gender, male/female | 70/53 | 31/32 | 39/21 | 0.077 |
BMI, kg/m2 | 26.9 ± 5.8 | 26.9 ± 5.5 | 27.0 ± 6.2 | 0.832 |
Diabetes duration, year | 8.4 ± 1.6 | 10.7 ± 8.4 | 7.8 ± 9.2 | 0.006* |
Diabetes complications | ||||
Neuropathy, n (%) | 64 (52.0) | 35 (55.6) | 29 (48.3) | 0.423 |
Retinopathy, n (%) | 26 (21.1) | 15 (23.8) | 11 (18.3) | 0.457 |
Nephropathy, n (%) | 32 (26.0) | 18 (28.6) | 14 (23.3) | 0.508 |
Micro-angiopathy, n (%) | 75 (61.0) | 40 (63.5) | 35 (58.3) | 0.558 |
Macro-angiopathy, n (%) | 20 (16.3) | 8 (12.7) | 12 (20.0) | 0.273 |
Fast blood glucose, mg/dl | 132.0 ± 30.4 | 133.6 ± 27.1 | 130.4 ± 33.7 | 0.284 |
HbA1c, % | 8.4 ± 1.6 | 8.5 ± 1.6 | 8.4 ± 1.5 | 0.658 |
eGFR, ml/min/1.73m2 | 75.5 ± 23.9 | 75.0 ± 22.7 | 76.0 ± 25.4 | 0.588 |
Number of medications, n (%) | ||||
1 drug | 48 (39.0) | 36 (60.0) | 12 (19.0) | < 0.001* |
2 drugs | 44 (35.8) | 20 (33.3) | 24 (38.1) | |
3 drugs | 30 (24.4) | 4 (6.7) | 26 (41.3) | |
4 drugs | 1 (0.8) | 0 (0) | 1 (1.6) | |
Medication, n (%) | ||||
SU | 63 (51.2) | 63 (100) | 0 (0) | - |
Glimepiride | 25 (20.3) | 25 (39.7) | 0 (0) | - |
Gliclazide | 36 (29.3) | 36 (57.1) | 0 (0) | - |
Glibenclamide | 2 (1.6) | 2 (3.2) | 0 (0) | - |
High-dose SU | 10 (8.1) | 10 (15.9) | 0 (0) | - |
TZD | 21 (17.0) | 11 (17.5) | 10 (16.7) | 0.907 |
BG | 49 (39.8) | 26 (41.3) | 23 (38.3) | 0.739 |
α-GI | 13 (10.6) | 7 (11.1) | 6 (10.0) | 0.841 |
Glinide | 2 (1.6) | 0 (0) | 2 (3.3) | 0.144 |
DPP4 inhibitor | 75 (61.0) | 32 (50.8) | 43 (71.7) | 0.018† |
GLP1RA | 4 (3.3) | 3 (4.8) | 1 (1.7) | 0.333 |
SGLT2 inhibitor | 1 (0.8) | 0 (0) | 1 (1.7) | 0.488 |
